Comparative Pharmacology
Head-to-head clinical analysis: TATUM T versus VOLNEA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TATUM T versus VOLNEA.
TATUM-T vs VOLNEA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TATUM-T is a combination of ethynodiol diacetate, a progestin, and ethinyl estradiol, an estrogen. It suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation. Additionally, it increases viscosity of cervical mucus, impeding sperm penetration, and alters the endometrium to reduce implantation likelihood.
Volnea is a combination of dienogest and ethinylestradiol. Dienogest is a progestin with antiandrogenic activity, and ethinylestradiol is an estrogen. The contraceptive effect is achieved through suppression of gonadotropins (FSH and LH), inhibition of ovulation, and changes in cervical mucus and endometrium.
One tablet (ethinyl estradiol 0.035 mg / norgestimate 0.250 mg) orally once daily for 21 days, followed by 7 days of placebo.
One tablet (0.02 mg ethinylestradiol + 3 mg drospirenone) orally once daily for 21 consecutive days, followed by a 7-day hormone-free interval.
None Documented
None Documented
Terminal elimination half-life of 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours in creatinine clearance <30 mL/min) requiring dose adjustment
Terminal half-life: 12 hours (range 10-14 h). Supports twice-daily dosing in patients with normal renal function.
Primarily renal (65-70% as unchanged drug); biliary/fecal (20-25%); minor metabolism to inactive glucuronide conjugates (<10%)
Renal: 70% unchanged; fecal: 30% (biliary elimination)
Category C
Category C
Oral Contraceptive
Oral Contraceptive